Publication: Pharmaceutical development and optimization of azithromycin suppository for paediatric use
Issued Date
2013-01-30
Resource Type
ISSN
18733476
03785173
03785173
Other identifier(s)
2-s2.0-84872827650
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Pharmaceutics. Vol.441, No.1-2 (2013), 218-226
Suggested Citation
Tina Kauss, Alexandra Gaubert, Chantal Boyer, Boubakar B. Ba, Muriel Manse, Stephane Massip, Jean Michel Léger, Fawaz Fawaz, Martine Lembege, Jean Michel Boiron, Xavier Lafarge, Niklas Lindegardh, Nicholas J. White, Piero Olliaro, Pascal Millet, Karen Gaudin Pharmaceutical development and optimization of azithromycin suppository for paediatric use. International Journal of Pharmaceutics. Vol.441, No.1-2 (2013), 218-226. doi:10.1016/j.ijpharm.2012.11.040 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/32749
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pharmaceutical development and optimization of azithromycin suppository for paediatric use
Abstract
Pharmaceutical development and manufacturing process optimization work was undertaken in order to propose a potential paediatric rectal formulation of azithromycin as an alternative to existing oral or injectable formulations. The target product profile was to be easy-to-use, cheap and stable in tropical conditions, with bioavailability comparable to oral forms, rapidly achieving and maintaining bactericidal concentrations. PEG solid solution suppositories were characterized in vitro using visual, HPLC, DSC, FTIR and XRD analyses. In vitro drug release and in vivo bioavailability were assessed; a study in rabbits compared the bioavailability of the optimized solid solution suppository to rectal solution and intra-venous product (as reference) and to the previous, non-optimized formulation (suspended azithromycin suppository). The bioavailability of azithromycin administered as solid solution suppositories relative to intra-venous was 43%, which compared well to the target of 38% (oral product in humans). The results of 3-month preliminary stability and feasibility studies were consistent with industrial production scale-up. This product has potential both as a classical antibiotic and as a product for use in severely ill children in rural areas. Industrial partners for further development are being sought. © 2012 Elsevier B.V. All rights reserved.